At SL BIO, we are proud to introduce CD-19 Armed-T Therapy, an advanced immunotherapy platform designed to explore precision T cell engagement using bispecific antibody technology. Armed-T cells are T cells modified to engage specific targets using bispecific antibodies that act as a molecular bridge between the T cell and the antigen- presenting cell.  Armed-T technology helps direct T cell interaction toward tumor- associated targets while aiming to reduce off-target activation. This approach is currently under preclinical investigation and supports ongoing efforts to develop targeted immune strategies for investigational applications in oncology.

 

Licensed from CytoArm, a recognized innovator in immune redirection, Armed-T reflects our commitment to next-generation research and high development standards. This approach supports ongoing efforts to develop targeted immune strategies for investigational applications in oncology.